TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

NCT02117427 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
End Stage Renal Disease

Interventions

BIOLOGICAL: MDGN201 TARGTEPO

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company

Collaborators

[object Object]